1-13 of 13
Xiaobo Zhong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Clinical Trials & Observations
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa McKiver, Paula Rodríguez-Otero
Journal: Blood
Blood (2024) 144 (23): 2389–2401.
https://doi.org/10.1182/blood.2024024582
Published: 2024
Includes: Supplemental data
Journal Articles

Global Manufacturing Experience with Idecabtagene Vicleucel in Patients with Relapsed and Refractory Multiple Myeloma

Surbhi Sidana, Christof Scheid, Peter J. Mueller, Petra Schuberth, Hardik Modi, Peter Krengel, Romain Piault, Xiaobo Zhong, Paula Rodríguez-Otero
Journal: Blood
Blood (2024) 144 (Supplement 1): 3476.
https://doi.org/10.1182/blood-2024-194645
Published: 2024
Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Madhav V. Dhodapkar, Melissa Alsina, Jesus G. Berdeja, Krina K. Patel, Shambavi Richard, Ravi Vij, Xavier Leleu, Daniel N. Egan, P. Leif Bergsagel, Ran Reshef, Saad Z Usmani, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Laurie Eliason, Xiaobo Zhong, Chiara Greggio, Sinhan Tran, Maria Chaudhry, Marlene J. Carrasco-Alfonso, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 2101.
https://doi.org/10.1182/blood-2023-173970
Published: 2023
Journal Articles

Busulfan / Melphalan / Bortezomib (Bu-Mel-Vel) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM)

Tulio E. Rodriguez, MD, Parameswaran Hari, MD, MS, Patrick J Stiff, MD, Xiaobo Zhong, MS, Danielle Sterrenberg, MD, David H. Vesole, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3357.
https://doi.org/10.1182/blood.V122.21.3357.3357
Published: 2013
Journal Articles

Alternative Donor Hematopoietic Transplantation For Patients Older Than 50 Years With AML In First Complete Remission: Unrelated Donor and Umbilical Cord Blood Transplantation Outcomes

Daniel J. Weisdorf, MD, Mary Eapen, MBBS, MS, Annalisa Ruggeri, MD, Mei-Jie Zhang, PhD, Xiaobo Zhong, MS, Claudio Brunstein, MD, Celalettin Ustun, Vanderson Rocha, MD, Eliane Gluckman, MD
Journal: Blood
Blood (2013) 122 (21): 302.
https://doi.org/10.1182/blood.V122.21.302.302
Published: 2013
Journal Articles

Multiple Myeloma (MM) In Older (>70 year) Patients - Similar Benefit From Autologous Hematopoietic Cell Transplantation (AHCT) Compared With Younger Patients

Manish Sharma, MD, Mei-Jie Zhang, PhD, Xiaobo Zhong, MS, Cristina J. Gasparetto, MD, Amrita Y. Krishnan, MD, Sagar Lonial, M.D., Parameswaran Hari, MD, MS
Journal: Blood
Blood (2013) 122 (21): 416.
https://doi.org/10.1182/blood.V122.21.416.416
Published: 2013
Journal Articles

Transplantation Of Peripheral Blood Progenitor Cells (PBPC) As Compared To Bone Marrow (BM) From Unrelated Related Donors For Hematologic Cancers Using Fludarabine-Alkylating Agent Based Reduced Intensity Conditioning Regimens

Mary Eapen, MBBS, MS, Brent R. Logan, PhD, Mary M. Horowitz, MD, MS, Xiaobo Zhong, MS, Miguel Angel Perales, MD, Stephanie J. Lee, MD, MPH, Vanderson Rocha, MD, Robert J. Soiffer, MD, Daniel J. Weisdorf, MD, Richard E Champlin, MD
Journal: Blood
Blood (2013) 122 (21): 550.
https://doi.org/10.1182/blood.V122.21.550.550
Published: 2013
Journal Articles

Hematopoietic Cell Transplant Co-Morbidity Index (HCTCI) and Multiple Myeloma (MM) Survival After Autologous Hematopoietic Cell Transplantation (AHCT)

Anuj Mahindra, Ayman A Saad, MD, Mei-Jie Zhang, PhD, Xiaobo Zhong, MS, Angela Dispenzieri, MD, Amrita Krishnan, MD, Sagar Lonial, MD, Marcelo C Pasquini, MD, MS, Parameswaran Hari, MBBS, MD, MRCP
Journal: Blood
Blood (2012) 120 (21): 4217.
https://doi.org/10.1182/blood.V120.21.4217.4217
Published: 2012
Journal Articles

Second Malignancies After Autologous Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Girindra Raval, Anuj Mahindra, MD, Xiaobo Zhong, MS, Ruta Brazauskas, PhD, Robert Peter Gale, MD, PhD, DSc, FACP, Nancy Brandenburg, PhD, Sagar Lonial, MD, Amrita Krishnan, MD, Angela Dispenzieri, MD, Parameswaran Hari, MBBS, MD, MRCP
Journal: Blood
Blood (2012) 120 (21): 591.
https://doi.org/10.1182/blood.V120.21.591.591
Published: 2012
Journal Articles

Trends in Utilization and Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) in the Upfront Management of Patients with Multiple Myeloma: A Cibmtr Analysis

Luciano J. Costa, MD, PhD, Xiaobo Zhong, MS, Mei-Jie Zhang, PhD, Sagar Lonial, MD, Amrita Krishnan, MD, Angela Dispenzieri, MD, Parameswaran Hari, MBBS, MD, MRCP
Journal: Blood
Blood (2012) 120 (21): 596.
https://doi.org/10.1182/blood.V120.21.596.596
Published: 2012
Journal Articles

Pre-Transplant Salvage Therapy Prior to Autologous Transplant (AHCT) in Patients Not Responding to Initial Induction for Multiple Myeloma (MM)

Ravi Vij, MBBS, Xiaobo Zhong, MS, Mei-Jie Zhang, PhD, Sagar Lonial, MD, Angela Dispenzieri, MD, Parameswaran Hari, MBBS, MD, MRCP
Journal: Blood
Blood (2012) 120 (21): 597.
https://doi.org/10.1182/blood.V120.21.597.597
Published: 2012
Journal Articles

Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) – a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)

Ayman A Saad, MD, David H. Vesole, MD, PhD, Jennifer Le-Rademacher, PhD, Xiaobo Zhong, MS, Angela Dispenzieri, MD, Sagar Lonial, MD, Gustavo A. Milone, MD, Parameswaran Hari, MBBS, MD, MRCP
Journal: Blood
Blood (2011) 118 (21): 504.
https://doi.org/10.1182/blood.V118.21.504.504
Published: 2011
Journal Articles

Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT)

Cesar O. Freytes, MD, David H. Vesole, MD, PhD, Xiaobo Zhong, MS, Jennifer Le-Rademacher, PhD, Angela Dispenzieri, MD, Sagar Lonial, MD, Gustavo Milone, Parameswaran Hari, MBBS, MD, MRCP
Journal: Blood
Blood (2011) 118 (21): 824.
https://doi.org/10.1182/blood.V118.21.824.824
Published: 2011